Dolutegravir/lamivudine
Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. each pill contains 50 mg dolutegravir, as the salt, an integrase strand transfer inhibitor, and 300 mg lamivudine, a nucleoside analogue reverse transcriptase inhibitor. It is taken by mouth.
It was approved for use in the United States in April 2019, and in the European Union in July 2019, and again with revisions in June 2022.
The most common side effects are headache, diarrhea, nausea, and difficulty sleeping. The most common serious side effects are allergic reactions, including rash and severe liver problems.
Dolutegravir/lamivudine is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
Medical uses
In the EU, dolutegravir/lamivudine is indicated for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents above 12 years of age weighing at least, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.In the US, it is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults.